Myeloproliferative neoplasm natural history, complications, and prognosis

Myeloproliferative Neoplasm Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating myeloproliferative neoplasm from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Myeloproliferative neoplasm natural history, complications, and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Myeloproliferative neoplasm natural history, complications, and prognosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Myeloproliferative neoplasm natural history, complications, and prognosis
on Myeloproliferative neoplasm natural history, complications, and prognosis
Myeloproliferative neoplasm natural history, complications, and prognosis in the news
Blogs on Myeloproliferative neoplasm natural history, complications, and prognosis
Directions to Hospitals Treating Myeloproliferative neoplasm
Risk calculators and risk factors for Myeloproliferative neoplasm natural history, complications, and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Prognosis

When properly diagnosed and carefully managed, some patients may survive for many years, depending on the specific disease they have. Recent advancements in CML treatment such as IFN alpha, bone marrow transplantation and recent development of an agent that inhibits the tyrosine kinase function of the BCR-ABL fusion protein, have substantially increased the life expectancy for patients with CML, so the median survival rates of 5-7 years are commonly reported. If similar mechanisms of pathogenesis do exist in the other MPNs, tyrosine kinase inhibitors or similar agents may significantly improve survival. For polycythemia vera and essential thrombocytopenia, overall life expectancy may not be severely shortened, in view of the fact that they occur most frequently in older individuals. If left untreated, patients with a MPNs may die within months after the onset of symptoms.